Engineered anti-HER2 drug delivery nanosystems for the treatment of breast cancer
Silvia Vanni, Tania Mariastella Caputo, Angela Maria Cusano, Angela Maria Cusano, Alessandro De Vita, Andrea Cusano, Andrea Cusano, Claudia Cocchi, Chiara Mulè, Sofia Principe, Chiara Liverani, Giorgia Celetti, Alberto Micco, Chiara Spadazzi, Giacomo Miserocchi, Toni Ibrahim, Laura Mercatali, Anna Aliberti
Abstract
-glycolic acid) (PLGA) nanoparticles encapsulated with TZ demonstrated similar or superior biological activity compared to free TZ. Notably, PLGA functionalized with TZ both internally and on the surface exhibited the highest effectiveness in terms of cell viability, increase of apoptosis markers, and inducing cell quiescence. This affirms the pivotal role of PLGA nanoparticles in preserving the integrity of TZ and enhancing its targeted delivery. Furthermore, we propose a breakthrough fiber-optic technology for the less invasive local delivery of PLGA-based nanocarriers that can be effectively used in clinical practice. In conclusion our studies lay the foundation for future advancements in alternative therapeutic tools for localized breast cancer treatment. The integration of advanced carriers, optical fibers, and microfluidics opens up new possibilities for innovative and targeted therapeutic approaches.